Page 76 - Read Online

Zhang et al. Cancer Drug Resist 2024;7:30 https://dx.doi.org/10.20517/cdr.2024.62 Page 13 of 13

cells via targeting Livin. Neoplasma 2020;67:102-10. DOI PubMed
67. Hao J, Du X, Lv F, Shi Q. Knockdown of circ_0006528 suppresses cell proliferation, migration, invasion, and adriamycin
chemoresistance via regulating the miR-1236-3p/CHD4 axis in breast cancer. J Surg Res 2021;260:104-15. DOI PubMed
68. Yang W, Gong P, Yang Y, Yang C, Yang B, Ren L. Circ-ABCB10 contributes to paclitaxel resistance in breast cancer through let-7a-
5p/DUSP7 axis. Cancer Manag Res 2020;12:2327-37. DOI PubMed PMC
69. Chen Z, Shi T, Zhang L, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance:
a review of the past decade. Cancer Lett 2016;370:153-64. DOI PubMed
70. Chen Y, Li X, Shi L, et al. Combination of 7-O-geranylquercetin and microRNA-451 enhances antitumor effect of Adriamycin by
reserving P-gp-mediated drug resistance in breast cancer. Aging 2022;14:7156-69. DOI PubMed PMC
71. Zhang Z, Zhou Q, Luo F, et al. Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/
LPAATβ axis. Hum Cell 2021;34:1558-68. DOI PubMed
72. Liang H, Lin Z, Lin H, Zhao L, Huang W. circRNA_103615 contributes to tumor progression and cisplatin resistance in NSCLC by
regulating ABCB1. Exp Ther Med 2021;22:934. DOI PubMed PMC
73. Lee JW, Guan W, Han S, Hong DK, Kim LS, Kim H. MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition
of epithelial-to-mesenchymal transition in breast cancer. Cancer Sci 2018;109:1404-13. DOI PubMed PMC
74. Wang G, Dong Y, Liu H, et al. Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting
ZEB1. Oncol Lett 2019;18:3837-44. DOI PubMed PMC
75. Liu YY, Zhang LY, Du WZ. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation
of ZEB1 expression by sponging miR-124-3p. Biosci Rep 2019;39:BSR20193045. DOI PubMed PMC
76. Jhaveri K, Marmé F. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor
receptor 2-negative metastatic breast cancer. Cancer Treat Rev 2024;123:102670. DOI PubMed
77. Nakagawa T, Hayashi K, Ogawa A, et al. Bone marrow carcinomatosis in a stage IV breast cancer patient treated by letrozole as first-
line endocrine therapy. Case Rep Oncol 2022;15:436-41. DOI PubMed PMC
78. Boscolo Bielo L, Trapani D, Nicolò E, et al. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast
Cancer. Cancer Treat Rev 2024;128:102761. DOI PubMed
79. He YJ, Wu JZ, Ji MH, et al. miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer. Exp
Ther Med 2013;5:813-8. DOI PubMed PMC
80. Yi J, Wang L, Hu GS, et al. CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS.
EMBO J 2023;42:e112408. DOI PubMed PMC
81. Ward A, Shukla K, Balwierz A, et al. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of
tumour-suppressor genes in ER+ breast cancer. J Pathol 2014;233:368-79. DOI PubMed PMC
82. Zheng L, Meng X, Li X, et al. miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in
estrogen receptor-positive breast cancer. FASEB J 2018;32:588-600. DOI PubMed
83. Chen J, Shi P, Zhang J, et al. CircRNA_0044556 diminishes the sensitivity of triple-negative breast cancer cells to adriamycin by
sponging miR-145 and regulating NRAS. Mol Med Rep 2022;25:51. DOI PubMed PMC
84. Misir S, Yaman SO, Petrović N, Sumer C, Hepokur C, Aliyazicioglu Y. circRNAs in drug resistance of breast cancer. Oncol Res
2022;30:157-72. DOI PubMed PMC
85. Ye X, Bai W, Zhu H, et al. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting
PTEN. BMB Rep 2014;47:268-73. DOI PubMed PMC
86. Wang S, Wang Y, Li Q, Li X, Feng X. A novel circular RNA confers trastuzumab resistance in human epidermal growth factor
receptor 2-positive breast cancer through regulating ferroptosis. Environ Toxicol 2022;37:1597-607. DOI PubMed
87. Ling Y, Liang G, Lin Q, et al. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast
cancer. Mol Cancer 2022;21:8. DOI PubMed PMC